Bioinformatics for Cancer Immunotherapy.

Our immune system plays a key role in health and disease as it is capable of responding to foreign antigens as well as acquired antigens from cancer cells. Latter are caused by somatic mutations, the so-called neoepitopes, and might be recognized by T cells if they are presented by HLA molecules on the surface of cancer cells. Personalized mutanome vaccines are a class of customized immunotherapies, which is dependent on the detection of individual cancer-specific tumor mutations and neoepitope (i.e., prediction, followed by a rational vaccine design, before on-demand production. The development of next generation sequencing (NGS) technologies and bioinformatic tools allows a large-scale analysis of each parameter involved in this process. Here, we provide an overview of the bioinformatic aspects involved in the design of personalized, neoantigen-based vaccines, including the detection of mutations and the subsequent prediction of potential epitopes, as well as methods for associated biomarker research, such as high-throughput sequencing of T-cell receptors (TCRs), followed by data analysis and the bioinformatics quantification of immune cell infiltration in cancer samples.

[1]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[2]  A. Ben-Hur,et al.  METHOD Open Access , 2014 .

[3]  Thomas Zichner,et al.  DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..

[4]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[5]  J. Castle,et al.  HLA typing from RNA-Seq sequence reads , 2012, Genome Medicine.

[6]  Juw Won Park,et al.  MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data , 2012, Nucleic acids research.

[7]  Bernhard Y. Renard,et al.  Confidence-based Somatic Mutation Evaluation and Prioritization , 2012, PLoS Comput. Biol..

[8]  Ravi Vijaya Satya,et al.  Comparison of somatic mutation calling methods in amplicon and whole exome sequence data , 2014, BMC Genomics.

[9]  O. Lund,et al.  NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ , 2013, Immunogenetics.

[10]  Robert A Holt,et al.  Sequence analysis of T-cell repertoires in health and disease , 2013, Genome Medicine.

[11]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[12]  H. Rammensee,et al.  The regulatory landscape for actively personalized cancer immunotherapies , 2013, Nature Biotechnology.

[13]  J. Sidney,et al.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity , 2014, The Journal of experimental medicine.

[14]  Mark M Davis,et al.  Linking T-cell receptor sequence to functional phenotype at the single-cell level , 2014, Nature Biotechnology.

[15]  Ö. Türeci,et al.  Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination , 2015, Journal of immunology research.

[16]  J. Castle,et al.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.

[17]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[18]  David E. Fisher,et al.  Precision medicine for cancer with next-generation functional diagnostics , 2015, Nature Reviews Cancer.

[19]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[20]  Michael Schantz Klausen,et al.  LYRA, a webserver for lymphocyte receptor structural modeling , 2015, Nucleic Acids Res..

[21]  T. Chan,et al.  The role of neoantigens in response to immune checkpoint blockade. , 2016, International immunology.

[22]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[23]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[24]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[25]  R. Yamada,et al.  HLA‐HD: An accurate HLA typing algorithm for next‐generation sequencing data , 2017, Human mutation.

[26]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, Genome Biology.

[27]  Jennifer G. Abelin,et al.  Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.

[28]  Z. Szallasi,et al.  An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes , 2017, Front. Immunol..

[29]  Xiaohui Xie,et al.  HLA class I binding prediction via convolutional neural networks , 2017, bioRxiv.

[30]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[31]  M. Nielsen,et al.  NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data , 2017, The Journal of Immunology.

[32]  T. Karlsen,et al.  Overview of methodologies for T-cell receptor repertoire analysis , 2017, BMC Biotechnology.

[33]  Zoltan Szallasi,et al.  MuPeXI: prediction of neo-epitopes from tumor sequencing data , 2017, Cancer Immunology, Immunotherapy.

[34]  S. Paik,et al.  Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Z. Trajanoski,et al.  Quantifying tumor-infiltrating immune cells from transcriptomics data , 2018, Cancer Immunology, Immunotherapy.

[36]  M. Nielsen,et al.  NetTCR: sequence-based prediction of TCR binding to peptide-MHC complexes using convolutional neural networks , 2018, bioRxiv.

[37]  W. Curran,et al.  T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient , 2018, Cancer Immunology, Immunotherapy.

[38]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[39]  Jan Baumbach,et al.  Comprehensive evaluation of cell-type quantification methods for immuno-oncology , 2018 .

[40]  N. McGranahan,et al.  Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Thomas Colthurst,et al.  A universal SNP and small-indel variant caller using deep neural networks , 2018, Nature Biotechnology.

[42]  Yabin Jin,et al.  TCR repertoire profiling of tumors, adjacent normal tissues, and peripheral blood predicts survival in nasopharyngeal carcinoma , 2018, Cancer Immunology, Immunotherapy.

[43]  Joachim Weischenfeldt,et al.  SvABA: genome-wide detection of structural variants and indels by local assembly , 2018, Genome research.

[44]  Yeonseok Chung,et al.  Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance , 2018, Experimental & Molecular Medicine.

[45]  Ö. Türeci,et al.  Personalized vaccines for cancer immunotherapy , 2018, Science.

[46]  Aurélien de Reyniès,et al.  Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine , 2018, Front. Oncol..

[47]  Yabin Jin,et al.  Circulating CD8+ T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients , 2018, Cancer Immunology, Immunotherapy.

[48]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[49]  Yuxin Cui,et al.  DeepSeqPan, a novel deep convolutional neural network model for pan-specific class I HLA-peptide binding affinity prediction , 2018, Scientific Reports.

[50]  Yu Wang,et al.  Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data , 2017, Genome Medicine.

[51]  Vanessa Isabell Jurtz,et al.  Computational Methods for Identification of T Cell Neoepitopes in Tumors. , 2019, Methods in molecular biology.

[52]  Jan Baumbach,et al.  Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology , 2019, Bioinform..